15 December 2023
15 December 2023
The latest development comes after senior US officials met the RSV manufacturers and their partners.
Teva will obtain exclusive development, manufacturing and commercialisation rights for BD9 across the globe.
The approval is based on data from a single-arm, multi-site, externally controlled trial.
Experts discussed the potential impacts of climate change on the pharma supply chain and how companies can prepare for them.
Acadia received two patent rulings that strengthen Nuplazid’s patent position and protect the drug into 2038.
Novo Nordisk will pay $92.5m in one-time cash payment to Alkermes, and the deal is expected to close in mid-2024.
A Phase II clinical trial treating 160 acute kidney injury patients with MTX652 is expected to be initiated in Q1 2024.
The payment, which includes the newly approved Casgevy, is the latest deal in a long line of CRISPR licensing twists and turns.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
